Alliancebernstein L.P. trimmed its holdings in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 6.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 171,200 shares of the biopharmaceutical company’s stock after selling 12,200 shares during the period. Alliancebernstein L.P. owned approximately 0.13% of Achillion Pharmaceuticals worth $786,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Wells Fargo & Company MN boosted its stake in Achillion Pharmaceuticals by 1.8% during the 2nd quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 3,827 shares during the last quarter. CIBC World Markets Inc. purchased a new stake in Achillion Pharmaceuticals during the 2nd quarter valued at $280,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Achillion Pharmaceuticals during the 2nd quarter valued at $597,000. JPMorgan Chase & Co. boosted its stake in Achillion Pharmaceuticals by 54.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 849,336 shares of the biopharmaceutical company’s stock valued at $3,897,000 after purchasing an additional 297,992 shares during the last quarter. Finally, Deschutes Portfolio Strategy LLC boosted its stake in Achillion Pharmaceuticals by 358.6% during the 2nd quarter. Deschutes Portfolio Strategy LLC now owns 116,630 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 91,200 shares during the last quarter. Institutional investors and hedge funds own 74.64% of the company’s stock.

Several analysts have commented on the company. Maxim Group set a $7.00 target price on Achillion Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub upgraded Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. ValuEngine downgraded Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th. Finally, Robert W. Baird downgraded Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. Achillion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $6.75.

COPYRIGHT VIOLATION WARNING: “Achillion Pharmaceuticals, Inc. (ACHN) Holdings Reduced by Alliancebernstein L.P.” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/10/31/achillion-pharmaceuticals-inc-achn-holdings-reduced-by-alliancebernstein-l-p.html.

Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 4.06 on Tuesday. The stock has a 50 day moving average price of $4.19 and a 200-day moving average price of $4.28. The stock’s market capitalization is $555.25 million. Achillion Pharmaceuticals, Inc. has a 1-year low of $3.15 and a 1-year high of $6.36.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same quarter in the previous year, the business earned ($0.14) EPS. Equities research analysts expect that Achillion Pharmaceuticals, Inc. will post ($0.66) EPS for the current year.

Achillion Pharmaceuticals Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.